Novakand Pharma AB (publ) (STO:NOVKAN)

Sweden flag Sweden · Delayed Price · Currency is SEK
0.1090
-0.0102 (-8.56%)
Mar 4, 2026, 5:09 PM CET
Market Cap14.45M -88.3%
Revenue (ttm)n/a
Net Income-47.23M
EPS-0.39
Shares Out121.19M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,006,046
Average Volume753,145
Open0.1360
Previous Close0.1192
Day's Range0.0920 - 0.1360
52-Week Range0.0752 - 2.2500
Beta1.02
RSI46.29
Earnings DateFeb 20, 2026

About Novakand Pharma AB

Novakand Pharma AB (publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase II study in healthy subjects to document desired dose levels against cancer; and Phase IIa study for the treatment of ovarian cancer. The company was formerly known as Kancera AB (publ) and changed its name to Novakand Pharma AB (publ) in Septembe... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 5
Stock Exchange Nasdaq Stockholm
Ticker Symbol NOVKAN
Full Company Profile

Financial Performance

Financial Statements